Alzheimer's-related peptide amyloid-β plays a conserved role in angiogenesis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Cameron, D Joshua ^a   Galvin, Cooper ^a   Alkam, Tursun ^a   Sidhu, Harpreet ^a   Ellison, John ^a   Luna, Salvadore ^a   Ethell, Douglas W ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA SECRETASE; MESSENGER RNA; NOTCH RECEPTOR;

ALZHEIMER DISEASE; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD VESSEL; BRANCHING MORPHOGENESIS; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE; GENE TARGETING; HES 1 GENE; HEY 1 GENE; HUMAN; HUMAN CELL; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RHOMBENCEPHALON;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; ZEBRAFISH;

DANIO RERIO;

EID: 84863622571     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039598     Document Type: Article

References (35)

1. Alzheimer's Association, Thies W, Bleiber L, (2011) Alzheimer's disease facts and figures. Alzheimer's Dement 7: 208.
2. Wyss-Coray A, (2006) Inflammation in Alzheimer's disease: driving force, bystander or beneficial response? Nature Medicine 12: 1005-1015.
3. Hanishch U-K, Kettenmann H, (2007) Microglia: active sensor and versatile effectors cells in the normal and pathologic brain. Nature Neurosci 10: 1387-1394.
4. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, et al. (1996) Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46: 707-719.
5. Selkoe DJ, (2000) The origins of Alzheimer disease: a is for amyloid. JAMA: the journal of the American Medical Association 283: 1615-1617.
6. De Strooper B, Vassar R, Golde T, (2010) The secretases: enzymes with therapeutic potential in Alzheimer's disease. Nature Reviews Neurology 6: 99-107.
7. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, et al. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer's Dement 7: 367-385.
8. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M, (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9: 702-716.
9. Joshi P, Liang JO, DiMonte K, Sullivan J, Pimplikar SW, (2009) Amyloid precursor protein is required for convergent movements during zebrafish development. Dev Biol 335: 1-11.
10. Ethell DW, (2010) An amyloid-notch hypothesis for Alzheimer's disease. The Neuroscientist 16: 614-617.
11. Wolfe MS, (2008) Gamma-secretase: structure, function, and modulation for Alzheimer's disease. Curr Top Med Chem 8: 2-8.
12. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, et al. (2002) A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 21: 1948-1956.
13. Liao YF, Wang BJ, Hsu WM, Lee H, Wu SY, et al. (2007) Unnatural amino acid-substituted (hydroxyethyl)urea peptidomimetics inhibit gamma-secretase and promote the neuronal differentiation of neuroblastoma cells. Mol Pharmacol 71: 588-601.
14. Nagase H, Koh CS, Nakayama K, (2011) gamma-Secretase-regulated signaling pathways, such as notch signaling, mediate the differentiation of hematopoietic stem cells, development of the immune system, and peripheral immune responses. Curr Stem Cell Res Ther 6: 131-141.
15. Hayashi H, (2007) Involvement of gamma-secretase in postnatal angiogenesis. Biochem Biophys Res Comm 363: 584-90.
16. Jorissen E, De Strooper B, (2010) Gamma-secretase and the intramembrane proteolysis of Notch. Curr Top Dev Biol 92: 201-230.
17. Artavanis-Tsakonas A, Muskavitch MA, (2010) Notch: the past, the present, and the future. Curr Top Dev Biol 92: 1-29.
18. Boulton ME, Cai J, Grant MB, (2008) gamma-Secretase: a multifaceted regulator of angiogenesis. J Cell Mol Med 12: 781-795.
19. Phng LK, Gerhardt H, (2009) Angiogenesis: a team effort coordinated by Notch. Dev Cell 16: 196-208.
20. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T, (2008) Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci USA 105: 3587-3592.
21. Malinda KM, Sidhu GS, Banaudha KK, Gaddipati JP, Maheshwari RK, et al. (1998) Thymosin alpha 1 stimulates endothelial cell migration, angiogenesis, and wound healing. J Immunol 160: 10011006.
22. Jin SW, Beis D, Mitchell T, Chen JN, Stainier DY, (2005) Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. Development 132: 5199-5209.
23. Cechetto DF, Hachinski V, Whitehead SN, (2008) Vascular risk factors and Alzheimer's disease. Expert Rev Neurotherap 8: 743-750.
24. Vagnucci AH Jr, Li WW, (2003) Alzheimer's disease and angiogenesis. Lancet 361: 605-608.
25. Biron KE, Dickstein DL, Gopaul R, Jefferies WA, (2011) Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS ONE 6: e23789.
26. Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, et al. (2005) Nicastrin functions as a gamma-secretase-substrate receptor. Cell 122: 435-447.
27. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, et al. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013.
28. Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870.
29. Selkoe DJ, (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17: 1060-1065.
30. Carlson C, Estergard W, Oh J, Suhy J, Jack CR Jr, et al. (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7: 396-401.
31. Wilcock DM, Colton CA, (2009) Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 8: 50-64.
32. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070.
33. Ethell DW, Kinlock R, Green DR, (2002) Metalloproteinase shedding of Fas lignad regulates beta-amyloid neurotoxicity. Curr Biol 12: 1595-1600.
34. Pontrello CG, Sun MY, Lin A, Fiacco TA, DeFea KA, et al. (2012) Cofilin under control of β-arrestin-2 in NMDA-dependent dendritic spine plasticity, long-term depression (LTD), and learning. Proc Natl Acad Sci USA 109: E441-51.
35. Westerfield M, (2007) in The Zebrafish Book. University of Oregon Press.